Advertisement

Mechanism of Thrombosis in the Antiphospholipid Syndrome: Binding to Platelets

  • J. C. Reverter
  • D. Tàssies

Abstract

Antiphospholipid antibodies (aPL) are related to thrombosis in the antiphospholipid syndrome [1, 2] and numerous pathophysiological mechanisms have been suggested involving cellular effects, plasma coagulation regulatory proteins and fibrinolysis [3]. Among the mechanisms supposed to be involved, platelets have been considered as a promising potential target to circulating aPL in causing antibody-mediated thrombosis.

Keywords

Systemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Platelet Activation Anticardiolipin Antibody Platelet Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486–489.PubMedGoogle Scholar
  2. 2.
    Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682–698.PubMedGoogle Scholar
  3. 3.
    Roubey RAS.Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 1444–1454.CrossRefGoogle Scholar
  4. 4.
    Machin SJ. Platelets and antiphospholipid antibodies. Lupus 1996; 5: 386–387.PubMedGoogle Scholar
  5. 5.
    Wiener HM, Vardinon N, Yust I. Platelet antibody binding and spontaneous aggregation in 21 lupus anticoagulant patients. Vox Sang 1991; 61: 111–121.PubMedCrossRefGoogle Scholar
  6. 6.
    Lin YL, Wang CT. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 1992; 80: 3135–3143.PubMedGoogle Scholar
  7. 7.
    Arvieux J, Roussel B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to β2-glycoprotein I. Thromb Haemost 1993; 70: 336–341.PubMedGoogle Scholar
  8. 8.
    Ford I, Urbaniak S, Greaves M. IgG from patients with antiphospholipid syndrome binds to platelets without induction of platelet activation. Br J Haematol 1998; 102: 841–849.PubMedCrossRefGoogle Scholar
  9. 9.
    Ostfeld I, Dadosh-Goffer N, Borokowski S, Talmon J, Mani A, Zor U et al. Lupus anticoagulant antibodies inhibit collagen-induced adhesion and aggregation of human platelets in vitro. J Clin Immunol 1992; 12: 415–423.PubMedCrossRefGoogle Scholar
  10. 10.
    Martinuzzo ME, Maclouf J, Carreras LO, Lèvy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667–671.PubMedGoogle Scholar
  11. 11.
    Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation. Thromb Haemost 1995; 73: 529–534.PubMedGoogle Scholar
  12. 12.
    Ichikawa Y, Kobayashi N, Kawada T, Shimizu H, Moriuchi J, Ono H et al. Reactivities of antiphospholipid antibodies to blood cells and their effect on platelet aggregations in vitro. Clin Exp Rheumatol 1990; 8: 461–465.PubMedGoogle Scholar
  13. 13.
    Reverter JC, Tàssies D, Escolar G, Font J, Lopez-Soto A, Ingelmo M et al. Effect of plasma from patients with primary antiphospholipid syndrome on platelet function in a collagen rich perfusion system. Thromb Haemost 1995; 73: 132–137.PubMedGoogle Scholar
  14. 14.
    Escolar G, Font J, Reverter JC, Lopez-Soto A, Garrido M, Cervera R et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation: studies in a perfusion system. Arterioscler Thromb 1992; 12: 196–200.PubMedCrossRefGoogle Scholar
  15. 15.
    Reverter JC, Tàssies D, Font J, Khamashta MA, Ichikawa K, Cervera R et al. Effect of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41: 1420–1427.PubMedCrossRefGoogle Scholar
  16. 16.
    Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B et al. Recurrent arterial thrombosis, repeated intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244–246.PubMedCrossRefGoogle Scholar
  17. 17.
    Carreras LO, Vermylen JG, Deman R, Spitz B, Van Asshe A. “Lupus” anticoagulant and thrombosis–possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 28–40.Google Scholar
  18. 18.
    Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 2894–2899.PubMedGoogle Scholar
  19. 19.
    Maclouf J, Lellouche F, Martinuzzo M, Said P, Carreras LO. Increased production of platelet derived thromboxane in patients with lupus anticoagulants. Agents Actions Suppl 1992; 37: 27–33.PubMedGoogle Scholar
  20. 20.
    Forastiero R, Martinuzzo M, Carreras LO, Maclouf J. Anti-β2-glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998; 79: 42–45.PubMedGoogle Scholar
  21. 21.
    Rustin MHA, Bull HA, Machin SJ. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 1988; 90: 744–748.PubMedCrossRefGoogle Scholar
  22. 22.
    Fanelli A, Bergamini C, Rapi S, Caldini A, Spinelli A, Buggiani A et al. Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies. Lupus 1997; 6: 261–267.PubMedCrossRefGoogle Scholar
  23. 23.
    Joseph JE, Donohoe S, Harrison P, Mackie IJ, Machin SJ. Platelet activation and turnover in the primary antiphospholipid syndrome. Lupus 1998; 7: 333–340.PubMedCrossRefGoogle Scholar
  24. 24.
    Shechter Y, Tal Y, Greenberg A, Brenner B. Platelet activation in patients with antiphospholipid syndrome. Blood Coag Fibrinol 1998; 9: 653–657.CrossRefGoogle Scholar
  25. 25.
    Out HJ, de Groot P, van Vliet M, de Gast G, Nieuwenhuis K, Derksen RHWM. Antibodies to platelets in patients with antiphospholipid antibodies. Blood 1991; 77: 2655–2659.PubMedGoogle Scholar
  26. 26.
    Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in the antiphospholipid syndrome. Thromb Haemost 1993; 69: 541.Google Scholar
  27. 27.
    Roubey RAS. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7 (suppl. 2): 114–119.CrossRefGoogle Scholar
  28. 28.
    Chong BH, Brighton TC, Chesterman CN. Antiphospholipid antibodies and platelets. Semin Thromb Hemost 1995; 21: 76–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Bevers EM, Comfurius P, Dekkers DWC, Harmsma M, Zwaal RFA. Regulatory mechanisms of trans-membrane phospholipid distributions and pathophysiological implications of transbilayer lipid scrambling. Lupus 1998; 7 (suppl. 2): 126–131.CrossRefGoogle Scholar
  30. 30.
    Schroit AJ, Zwaal RFA. Transbilayer movement of phospholipid in red cell and platelet membranes. Biochim Biophys Acta 1991; 1071: 313–329.PubMedCrossRefGoogle Scholar
  31. 31.
    Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott’s syndrome: an isolated defect in procoagulant activity. J Biol Chem 1989; 264: 17049–17057.PubMedGoogle Scholar
  32. 32.
    Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988; 47: 849–854.PubMedCrossRefGoogle Scholar
  33. 33.
    Shi W, Chong BH, Chesterman CN. β2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81: 1255–1262.PubMedGoogle Scholar
  34. 34.
    Galli M, Revers EM, Comfurius P, Barbui T, Zwaal RFA. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 1993; 83: 466–472.PubMedCrossRefGoogle Scholar
  35. 35.
    Galli M, Béguin S, Lindhout T, Hemker CH. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulant. Br J Haematol 1989; 72: 549–555.PubMedCrossRefGoogle Scholar
  36. 36.
    Galli M, Ruggeri L, Barbui T. Differential effects of anti-β2-glycoprotein I and anti-prothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 1999–2004.PubMedGoogle Scholar
  37. 37.
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–4124.PubMedCrossRefGoogle Scholar
  38. 38.
    Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547.PubMedCrossRefGoogle Scholar
  39. 39.
    Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactors and diferential diagnoses of autoimmune diseases. Lancet 1990; 336: 177–178.PubMedCrossRefGoogle Scholar
  40. 40.
    Matsuura E, Igarashi V, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457–462.PubMedCrossRefGoogle Scholar
  41. 41.
    Wurm H. Beta 2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511–515.PubMedCrossRefGoogle Scholar
  42. 42.
    Arnout J, Vermylen J. Mechanism of action of β-2-glycoprotein I-dependent lupus anticoagulants. Lupus 1998; 7 (suppl. 2): 23–28.CrossRefGoogle Scholar
  43. 43.
    Hunt JE, Krilis S. The fifth domain of β-2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653–659.PubMedGoogle Scholar
  44. 44.
    Igarashi M, Matsuura E, Igarashi Y, Nagae H, Ichikawa K, Triplett DA et al. Human β-2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a Baculovirus system. Blood 1996; 87: 3262–3270.PubMedGoogle Scholar
  45. 45.
    Willems GM, Janssen MP, Pelsers MMAL, Confurius P, Galli M, Zwaal RFA et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-β2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833–13842.PubMedCrossRefGoogle Scholar
  46. 46.
    Arvieux J, Jacob MC, Roussel B, Bensa JC, Colomb MG. Neutrophil activation by anti-β2-glycoprotein I monoclonal antibodies via Fcy receptor II. J Leukocyte Biol 1995; 57: 387–394.PubMedGoogle Scholar
  47. 47.
    van de Winkel JGJ, Capel PJA. Human IgG Fc receptor heterogeneity. Immunol Today 1993; 14: 215–221.PubMedCrossRefGoogle Scholar
  48. 48.
    Anderson CL, Chacko GW, Osborne JM, Brandt JT. The Fc receptor for immunoglobulin G (FcyRII) on human platelets. Semin Thromb Hemost 1995; 21: 1–9.PubMedCrossRefGoogle Scholar
  49. 49.
    De Reys S, Blom C, Lepoudre B, Declerck PJ, De Ley M, Vermylen J et al. Human platelet aggregation by murine monoclonal antibodies is subtype-dependent. Blood 1993; 81: 1792–1800.PubMedGoogle Scholar
  50. 50.
    Vermylen J, Hoylaerts MF, Arnout J. Antibody-mediated thrombosis. Thromb Haemost 1997; 78: 420–426.PubMedGoogle Scholar
  51. 51.
    Warmerdam PAM, van de Winkel JGJ, Vlug A, Westerdaal NAC, Capel PJA. A single amino acid in the second Ig-like domain of the FcyRII is critical for human IgG2 binding. J Immunol 1991; 147: 1338–1343.PubMedGoogle Scholar
  52. 52.
    Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 536–541.PubMedGoogle Scholar
  53. 53.
    Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. “Anti-cardiolipin” autoantibodies recognize β2-glycoprotein I in the absence of phospholipid: importance of antigen density and bivalent binding. J Immunol 1995; 154: 954–960.PubMedGoogle Scholar
  54. 54.
    Wagenknecht DR, McIntyre JA. Changes in β2-glycoprotein I antigenicity induced by phospholipid binding. Thromb Haemost 1993; 69: 361–365.PubMedGoogle Scholar
  55. 55.
    Arnout J, Wittelvrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. β2-glycoprotein I dependent lupus anticoagulants form stable divalent antibody-β2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79: 79–86PubMedGoogle Scholar
  56. 56.
    Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993–997.PubMedCrossRefGoogle Scholar
  57. 57.
    Arvieux J, Roussel B, Ponard D, Golomb MG. IgG2 subclass restriction of anti β2-glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310–315.PubMedCrossRefGoogle Scholar
  58. 58.
    Atsumi T, Caliz R, Amengual O, Khamashta MA, Hughes GRV. FcyReceptor IIA H/R131 polymorphism in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 924–927.PubMedGoogle Scholar
  59. 59.
    McCrae KR, Shattil SJ, Cines DB. Platelet activation induces increased Fcy receptor expression. J Immunol 1990; 144: 3920–3927.PubMedGoogle Scholar
  60. 60.
    Gharavi AE, Pierangeli SS, Gharavi EE, Hua T, Liu XW, Barker JH et al. Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to β-2-glycoprotein I β2GPI) alone. Lupus 1998; 7: 341–346.PubMedCrossRefGoogle Scholar
  61. 61.
    Nojima J, Suehisa E, Kuratsune H, Machii T, Koike T, Kitani T et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus. Thromb Haemost 1999; 81: 436–441.PubMedGoogle Scholar
  62. 62.
    Shibata S, Sasaki T, Hirabayashi Y, Seino J, Okamura K, Yoshinaga K et al. Risk factors in the pregnancy of patients with systemic lupus erythematosus: association of hypocomplementaemia with poor prognosis. Ann Rheum Dis 1992; 51: 619–623.PubMedCrossRefGoogle Scholar
  63. 63.
    Hess DC, Sheppard JC, Adams RJ. Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies. Stroke 1993; 24: 994–999.PubMedCrossRefGoogle Scholar
  64. 64.
    Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992; 10: 455–460.PubMedGoogle Scholar
  65. 65.
    Rinder CS, Rinder HM, Smith BR, Ficht JC, Smith MJ, Tracey JB et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96: 1564–1572.PubMedCrossRefGoogle Scholar
  66. 66.
    Solum NO, Rubach-Dahlberg E, Pedersen TM, Reisberg T, Hogasen K, Funderud S. Complement-mediated permeabilization of platelets by monoclonal antibodies to CD9: inhibition by leupeptin, and effects on the GPI-acting-binding protein system. Thromb Res 1994; 75: 437–452.PubMedCrossRefGoogle Scholar
  67. 67.
    Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993; 82: 1192–1196.PubMedGoogle Scholar
  68. 68.
    Santiago MB, Gaburo N, de Oliveira RM, Cossermelli W. Complement activation by anticardiolipin antibodies. Ann Rheum Dis 1991; 50: 249–250.PubMedCrossRefGoogle Scholar
  69. 69.
    Stewart MW, Etches WS, Gordon PA. Antiphospholipid antibody-dependent C5b-9 formation. Br J Haematol 1997; 96: 451–457.PubMedCrossRefGoogle Scholar
  70. 70.
    Chang CP, Zhao J, Wiedmer T, Sims PJ. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J Biol Chem 1993; 268: 7171–7178.PubMedGoogle Scholar
  71. 71.
    Rock G, Chauhan K, Jamieson GA, Tandon NN. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol 1994; 88: 878–880.PubMedCrossRefGoogle Scholar
  72. 72.
    Tokita S, Arai M, Yamamoto M, Katagiri Y, Tanoue K, Igarashi K et al. Specific cross-reaction of IgG antiphospholipid antibody with platelet glycoprotein IIIA. Thromb Haemost 1996; 75: 168–174.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2000

Authors and Affiliations

  • J. C. Reverter
  • D. Tàssies

There are no affiliations available

Personalised recommendations